Label: BENZONATATE capsule
71335-2021-4, view more71335-2021-5, 71335-2021-6, 71335-2021-7, 71335-2021-8, 71335-2021-9
- Packager: Bryant Ranch Prepack
- This is a repackaged label.
- Source NDC Code(s): 62332-427
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
Updated February 10, 2022
If you are a consumer or patient please visit this version.
Benzonatate, a non-narcotic antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7.
Benzonatate Capsules, USP contain 100 mg or 200 mg of benzonatate, USP.
Benzonatate Capsules also contain: D&C Yellow No. 10, gelatin, glycerin, methylparaben sodium and propylparaben sodium.
Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage.
- INDICATIONS AND USAGE
(What is this?)
Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures.
Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking benzonatate in combination with other prescribed drugs.
Accidental Ingestion and Death in Children
Keep benzonatate out of reach of children.
Accidental ingestion of benzonatate resulting in death has been reported in children below age 10.
Signs and symptoms of overdose have been reported within 15 to 20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE).
Benzonatate is chemically related to anesthetic agents of the para-amino-benzoic acid class (e.g., procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.
Information for Patients:
Swallow benzonatate capsules whole. Do not break, chew, dissolve, cut, or crush benzonatate capsules. Release of benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur. If numbness or tingling of the tongue, mouth, throat, or face occurs, refrain from oral ingestion of food or liquids until the numbness has resolved. If the symptoms worsen or persist, seek medical attention.
Keep benzonatate out of reach of children. Accidental ingestion resulting in death has been reported in children. Signs and symptoms of overdose have been reported within 15 to 20 minutes and death has been reported within one hour of ingestion. Signs and symptoms may include restlessness, tremors, convulsions, coma and cardiac arrest. If accidental ingestion occurs, seek medical attention immediately.
Overdosage resulting in death may occur in adults.
Do not exceed a single dose of 200 mg and a total daily dose of 600 mg. If you miss a dose of benzonatate, skip that dose and take the next dose at the next scheduled time. Do not take 2 doses of benzonatate at one time.
Usage in Pregnancy:
Pregnancy Category C.
Animal reproduction studies have not been conducted with benzonatate. It is also not known whether benzonatate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate should be given to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when benzonatate is administered to a nursing woman.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
Carcinogenicity, mutagenicity, and reproduction studies have not been conducted with benzonatate.
Potential Adverse Reactions to benzonatate may include:
Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.
CNS: sedation; headache; dizziness; mental confusion; visual hallucinations.
GI: constipation, nausea, GI upset.
Dermatologic: pruritus; skin eruptions.
Other: nasal congestion; sensation of burning in the eyes; vague “chilly” sensation; numbness of the chest; hypersensitivity.
Deliberate or accidental overdose has resulted in death, particularly in children.
Intentional and unintentional overdose may result in death, particularly in children.
The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.
Signs and Symptoms:
The signs and symptoms of overdose of benzonatate have been reported within 15 to 20 minutes. If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly, which may cause choking and airway compromise.
CNS stimulation may cause restlessness and tremors, which may proceed to clonic convulsions followed by profound CNS depression. Convulsions, coma, cerebral edema and cardiac arrest leading to death have been reported within 1 hour of ingestion.
In case of overdose, seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag refluxes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage.
Do not use CNS stimulants.
DOSAGE AND ADMINISTRATION
Adults and Children over 10 years of age:
Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. Benzonatate should be swallowed whole. Benzonatate Capsules are not to be broken, chewed, dissolved, cut or crushed.
NDC: 71335-2021-1: 30 Capsules in a BOTTLE
NDC: 71335-2021-2: 100 Capsules in a BOTTLE
NDC: 71335-2021-3: 45 Capsules in a BOTTLE
NDC: 71335-2021-4: 20 Capsules in a BOTTLE
NDC: 71335-2021-5: 15 Capsules in a BOTTLE
NDC: 71335-2021-6: 21 Capsules in a BOTTLE
NDC: 71335-2021-7: 60 Capsules in a BOTTLE
NDC: 71335-2021-8: 50 Capsules in a BOTTLE
NDC: 71335-2021-9: 90 Capsules in a BOTTLE
- PRINCIPAL DISPLAY PANEL
INGREDIENTS AND APPEARANCE
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:71335-2021(NDC:62332-427) Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength BENZONATATE (UNII: 5P4DHS6ENR) (BENZONATATE - UNII:5P4DHS6ENR) BENZONATATE 200 mg Inactive Ingredients Ingredient Name Strength D&C YELLOW NO. 10 (UNII: 35SW5USQ3G) GELATIN, UNSPECIFIED (UNII: 2G86QN327L) GLYCERIN (UNII: PDC6A3C0OX) METHYLPARABEN SODIUM (UNII: CR6K9C2NHK) PROPYLPARABEN SODIUM (UNII: 625NNB0G9N) Product Characteristics Color YELLOW Score no score Shape CAPSULE Size 16mm Flavor Imprint Code A6 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:71335-2021-1 30 in 1 BOTTLE; Type 0: Not a Combination Product 02/10/2022 2 NDC:71335-2021-2 100 in 1 BOTTLE; Type 0: Not a Combination Product 02/10/2022 3 NDC:71335-2021-3 45 in 1 BOTTLE; Type 0: Not a Combination Product 02/10/2022 4 NDC:71335-2021-4 20 in 1 BOTTLE; Type 0: Not a Combination Product 02/10/2022 5 NDC:71335-2021-5 15 in 1 BOTTLE; Type 0: Not a Combination Product 02/10/2022 6 NDC:71335-2021-6 21 in 1 BOTTLE; Type 0: Not a Combination Product 02/10/2022 7 NDC:71335-2021-7 60 in 1 BOTTLE; Type 0: Not a Combination Product 02/10/2022 8 NDC:71335-2021-8 50 in 1 BOTTLE; Type 0: Not a Combination Product 02/10/2022 9 NDC:71335-2021-9 90 in 1 BOTTLE; Type 0: Not a Combination Product 02/10/2022 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA040682 05/01/2018 Labeler - Bryant Ranch Prepack (171714327) Registrant - Bryant Ranch Prepack (171714327) Establishment Name Address ID/FEI Business Operations Bryant Ranch Prepack 171714327 REPACK(71335-2021) , RELABEL(71335-2021)